01 / DESIGN
Viral vector design and construction
Design the vector genome—promoter, transgene, and packaging elements—around the delivery system you selected.
Gene Delivery Resource
Gene Delivery System Selection Guides: How to Choose the Right Delivery Approach
Choosing a gene delivery system requires matching the cargo, target tissue or cell, administration route, expression window, intracellular release needs, repeat-dosing plan, and validation endpoint. Viral vectors can support efficient or durable delivery in compatible models, while LNPs, polymers, and physical methods offer flexible approaches for transient RNA, DNA, or editing cargo. A suitable platform should be selected by productive biological delivery rather than uptake or particle quantity alone, with support from gene delivery system development, LNP formulation, and lentiviral vector development.
01 CargoDNA, mRNA, siRNA, or an editing complex?
02 RouteCell-based, ex vivo, local, or systemic delivery?
03 BarrierEntry, intracellular release, or expression?
04 EvidenceMeasure the intended effect and model suitability.
Direct Answer
Which Delivery Barrier Must the System Solve?
The starting decision is not simply viral versus non-viral. Identify where delivery is likely to fail: reaching the target, entering the appropriate cells, releasing active cargo, or achieving the intended intracellular effect.
Some intravenously administered LNP formulations favor the liver, but distribution is not a fixed property of all nanoparticles. Formulation and route can alter organ delivery, as illustrated by SORT research in preclinical models.[1] This does not establish that a formulation transfers unchanged across species or use settings.
The key principle: match the delivery approach to the limiting barrier and confirm the intended biological effect with relevant functional readouts.
Target access
Can the formulation or vector reach the tissue by the proposed route?
Evidence that matters: Model- and route-specific distribution, including relevant off-target tissues.
Cell entry
Does the target-cell receptor or uptake context support delivery?
Evidence that matters: Target-cell entry and viability; uptake may occur without functional delivery.
Intracellular availability
Will active cargo reach the cytosol or nucleus as required?
Evidence that matters: An activity-related assay that distinguishes uptake from productive release.
Expression or perturbation
Is the payload appropriate to the requested effect and time window?
Evidence that matters: Transcript, protein, editing, or other relevant functional readouts.
Repeat exposure
Is repeated administration needed and biologically tolerable?
Evidence that matters: Product- and model-specific activity and tolerability across the intended exposure schedule.
Compare Delivery Classes by the Decision They Enable
These are typical considerations, not universal product specifications. Count the complete cassette or cargo formulation, and compare endpoints using appropriate methods.
| Delivery class | Cargo and persistence | Model considerations | Key limitation |
|---|---|---|---|
| AAV | DNA cassette; conventional ssAAV has an approximately 4.7 kb genome budget including ITRs. Expression can persist in suitable tissues. | Capsid, route, species, cell turnover, and immune context. | Cassette capacity and delivery compatibility; repeat exposure requires evaluation. |
| Lentiviral | Usually an integrating DNA outcome following reverse transcription; integration-deficient architectures also exist. | Useful for many cell-engineering projects and compatible target models. | Integration-related questions, envelope compatibility, and expression heterogeneity. |
| Adenoviral | DNA delivery with architecture-dependent available insert space and expression duration. | Capsid/receptor compatibility, route, and the desired immune response. | Immune interactions and production or helper-system requirements. |
| Lipid or polymer carrier | RNA or DNA according to the formulation; transient cargo does not imply a transient biological outcome. | Route, formulation, uptake, release, cargo stability, and tolerability. | Productive intracellular delivery and repeat-exposure suitability must be demonstrated. |
| Physical delivery | DNA, RNA, or protein complexes according to the method. | Can suit accessible or isolated cells; tissue applications are method-specific. | Delivery efficiency must be balanced with viability and preserved cell function. |
Physical approaches belong in the selection framework, especially for cell-based or ex vivo work. Explore electroporation alongside LNP formulation rather than assuming that one class is always preferable.
For a vector-focused comparison, see viral vector selection guides.
Match the Cargo to the Required Effect
Specify what must be delivered and what must remain after delivery. The persistence of the carrier, cargo, expression product, and biological change are different questions.
| Objective | Relevant cargo direction | Selection question |
|---|---|---|
| Protein expression without permanent genetic change | An mRNA formulation or suitable nonintegrating expression system. | Does the achieved expression window match the study, and would repeat exposure be required? |
| Gene silencing | Synthetic siRNA or vector-expressed RNAi architecture. | Is the intended knockdown short-term, sustained, or regulated? |
| Genome editing | Appropriate delivery of editing RNA, DNA, or a protein–RNA complex. | Can exposure to editing components be limited while the intended edit persists? |
| Cell engineering | Integrating or other validated modification strategy where suitable. | Can modified cells retain identity, viability, and function after processing? |
Clinical LNP-mediated editing work illustrates that a transient cargo can produce a persistent genomic effect; it does not demonstrate that every LNP or editing formulation is suitable for every target. AAV studies likewise show that episomal expression can persist in an appropriate model.
For RNAi projects, discuss RNAi delivery development; for editing cargo, connect the design to LNP formulation for CRISPR components.
Selection Guides
Choose by your delivery scenario
Use these guides to narrow delivery options by administration route, tissue target, cargo, and carrier class. Start with the intended biological effect, then compare target-cell access, the required activity window, and the evidence needed to select an approach for your model.
Ex Vivo vs. In Vivo Delivery
Decide whether to modify cells outside the body or deliver cargo directly to the target tissue. Compare access to the target cells, opportunities to assess modified cells before use, and the required activity window. For ex vivo workflows, include cell recovery, viability, and retained function in the selection criteria.
Read the guideTissue-Targeted Delivery Strategy
Connect the target tissue and cell type to the administration route, capsid or carrier properties, and expression-control elements where relevant. Evaluate delivery to the intended cells alongside off-target distribution and biological activity. Select readouts that distinguish tissue exposure from productive expression, silencing, or editing in the required cell population.
Read the guideStrategies for Gene Delivery
Compare viral, chemical, and physical approaches against your cargo, target model, and intended effect. Consider whether the study requires transient expression, sustained silencing, or a lasting genomic change. Use a focused pilot to assess delivery, biological activity, and model suitability before committing to a platform or expanding the study.
Read the guideViral Vectors
Compare gammaretroviral, lentiviral, adenoviral, AAV, HSV, vaccinia, and baculoviral systems in the context of the intended application. Review cargo capacity, target-cell compatibility, expression duration, integration or replication design, and production requirements. Choose a backbone using evidence from a relevant model rather than assuming that all viral vectors behave similarly.
Read the guidePhysical Delivery
Consider electroporation, hydrodynamic injection, and other physical approaches when the target cells or tissue can be accessed by the selected method. Match the procedure to the cargo and experimental setting, then assess delivery alongside viability, cell recovery, and preserved function. Include practical handling and reproducibility when comparing candidate conditions.
Read the guideChemical Methods
Compare lipid-based formulations, cationic polymers, and protein-based carriers for the intended nucleic acid cargo and target model. Assess formulation compatibility, stability, cellular uptake, and productive intracellular release together. Rank candidate conditions using expression, knockdown, or editing outcomes alongside tolerability, rather than relying on an uptake signal alone.
Read the guideDecision Framework
Separate Uptake from Productive Delivery
A bright uptake signal is not sufficient to rank delivery systems. Cargo may be degraded or retained in intracellular compartments without producing the desired effect.
Strong uptake; weak expression or knockdown
Interpretation question: Is the cargo released and still active?
Next evidence: Cargo-related activity, intracellular availability, and relevant assay controls.
Strong expression; poor viability
Interpretation question: Is the apparent benefit offset by formulation, exposure, or payload stress?
Next evidence: Viability and the intended cell function alongside expression.
Activity in a cell line; weak activity in primary cells
Interpretation question: Does the model differ in uptake, entry, intracellular trafficking, or target biology?
Next evidence: Matched target-cell testing rather than extrapolation from a convenient assay line.
Loss of effect after repeat exposure
Interpretation question: Is the limitation immune, tolerability-related, or analytical?
Next evidence: A product-specific repeat-exposure comparison using appropriate activity and model readouts.
Imaging studies of LNP-siRNA delivery demonstrate why endosomal uptake and productive intracellular release must be distinguished.[2] Pair delivery measurements with the requested biological endpoint. For isolated-cell workflows, physical delivery methods may offer a useful alternative to a carrier-based approach.
Platform Trade-Offs
Advantages and Limitations
Viral platforms, chemical carriers, and physical methods offer different strengths. A useful selection guide connects those strengths to the actual cargo and model rather than ranking all systems by one attribute.
Viral Delivery
Viral delivery can provide efficient transfer and durable expression in compatible settings, but capsid or envelope compatibility, integration behavior, immunity, and manufacturing requirements vary.
Non-Viral Formulations
Non-viral formulations offer cargo flexibility and may permit repeat administration, but size, formulation stability, intracellular release, and tolerability remain constraints.
Physical Methods
Physical methods can bypass some carrier-related barriers yet impose their own stress and accessibility limits.
Immunogenicity
Do not assign "very low" or "low" immunogenicity to a complete platform class. Host context, payload, route, dose, formulation, and repeated exposure can change the response.
Off-Target Effects
Off-target uptake and off-target biological activity are also distinct; neither is resolved by a carrier label alone.
From Selection to Product
Creative Biolabs Support
Once you have chosen a delivery system, Creative Biolabs carries it through design, construction, production, and analysis.
02 / PRODUCTION
Custom viral vector production
Produce high-titer lentivirus, adenovirus, AAV, retrovirus, or herpes simplex virus at the scale your experiment requires.
03 / NON-VIRAL
Lipid nanoparticle formulation
Discuss cargo-compatible LNP formulation, productive intracellular delivery, and the activity and tolerability endpoints required for the intended route. Repeat-exposure suitability is project-specific.
04 / ANALYSIS
Viral vector analysis
Define the identity, quantity, activity, impurity, and relevant safety questions for the selected vector, and confirm the available assays and reporting scope.
Selected Reading
Scientific context for delivery-system selection
Tissue Delivery
Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nature Nanotechnology. 2020;15(4):313-320. https://doi.org/10.1038/s41565-020-0669-6.
Productive Delivery
Gilleron J, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nature Biotechnology. 2013;31(7):638-646. https://doi.org/10.1038/nbt.2612.
Transient Cargo, Durable Effect
Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine. 2021;385(6):493-502. https://doi.org/10.1056/NEJMoa2107454.
Expression Persistence
Guilbaud M, et al. Five years of successful inducible transgene expression following locoregional adeno-associated virus delivery in nonhuman primates with no detectable immunity. Human Gene Therapy. 2019;30(7):802-813. https://doi.org/10.1089/hum.2018.234.
FAQ
Gene delivery selection questions
No. Choose according to the cargo, target model, route, expression requirements, and validation endpoints. Each class has distinct delivery and suitability constraints.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
